CollPlant Biotechnologies (NASDAQ:CLGN) Earns “Buy” Rating from HC Wainwright

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 158.91% from the stock’s current price.

Other research analysts have also issued research reports about the company. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of CollPlant Biotechnologies in a research report on Wednesday.

CollPlant Biotechnologies Stock Down 0.4 %

CLGN traded down $0.02 on Friday, hitting $4.25. The company had a trading volume of 21,051 shares, compared to its average volume of 18,116. The company has a market cap of $48.65 million, a PE ratio of -2.76 and a beta of 0.44. CollPlant Biotechnologies has a 12-month low of $3.31 and a 12-month high of $6.99. The business’s fifty day simple moving average is $4.30 and its 200 day simple moving average is $4.85.

Institutional Trading of CollPlant Biotechnologies

Several institutional investors and hedge funds have recently modified their holdings of CLGN. Pinnacle Associates Ltd. raised its stake in shares of CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after acquiring an additional 33,905 shares in the last quarter. Villere ST Denis J & Co. LLC raised its stake in shares of CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after acquiring an additional 95,000 shares in the last quarter. Finally, Benjamin Edwards Inc. bought a new stake in shares of CollPlant Biotechnologies during the third quarter valued at approximately $112,000. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.